R-CHOP or R-HyperCVAD With or Without Autologous Stem Cell Transplantation for Older Patients With Mantle Cell Lymphoma.

CONCLUSION: R-CHOP alone is less effective therapy for fit older patients with MCL. Intensifying therapy with R-HyperCVAD induction or ASCT consolidation after R-CHOP is associated with prolonged PFS and similar rates of toxicity. Consideration should be given to individual preferences regarding the differing method of administration and relative timing of toxicity with each regimen.
PMID: 25174772 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - August 1, 2014 Category: Cancer & Oncology Authors: Frosch Z, Luskin MR, Landsburg DJ, Schuster SJ, Svoboda J, Loren AW, Porter DL, Stadtmauer EA, Nasta SD Tags: Clin Lymphoma Myeloma Leuk Source Type: research